Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
Journal of Traumatic Stress
|
July 16, 2004
A concise measure of anger in combat-related posttraumatic stress disorder
David Forbes, Graeme Hawthorne, Peter Elliott, et al.
Journal of Traumatic Stress
|
January 2, 2007
Is mixed-handedness a marker of treatment response in posttraumatic stress disorder?: a pilot study
David Forbes, Jessica Carty, Peter Elliott, et al.
European Journal of Preventive Cardiology
|
June 5, 2013
Red flags for persistent or worsening anxiety and depression after an acute cardiac event: a 6-month longitudinal study in regional and rural Australia
Barbara Murphy, Deborah Ludeman, Peter Elliott, et al.
Journal of Cardiopulmonary Rehabilitation and Prevention
|
March 13, 2013
Predicting mortality 12 years after an acute cardiac event: comparison between inhospital and 2-month assessment of depressive symptoms in women
Barbara Murphy, Michelle Rogerson, Marian Worcester, et al.
British Journal of Clinical Pharmacology
|
May 24, 2012
Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man
Ethan Hoffmann, Jeff Wald, Siva Lavu, et al.
Nano Letters
|
August 19, 2021
Spin/Valley Coupled Dynamics of Electrons and Holes at the MoS<sub>2</sub>-MoSe<sub>2</sub> Interface
Abhijeet Kumar, Denis Yagodkin, Nele Stetzuhn, et al.
Journal of Affective Disorders
|
February 5, 2013
A trajectory-based approach to understand the factors associated with persistent depressive symptoms in primary care
Jane Gunn, Peter Elliott, Konstancja Densley, et al.
British Journal of Haematology
|
December 5, 2012
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma
Rakesh Popat, Torben Plesner, Faith Davies, et al.
British Journal of Clinical Pharmacology
|
January 23, 2014
A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes
Arun Baksi, Oleg Kraydashenko, Alsu Zalevkaya, et al.
Cancer Research
|
December 7, 2007
The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action
Margaret S Lee, Lisa Johansen, Yanzhen Zhang, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
Journal of Traumatic Stress
|
July 16, 2004
A concise measure of anger in combat-related posttraumatic stress disorder
David Forbes, Graeme Hawthorne, Peter Elliott, et al.
Journal of Traumatic Stress
|
January 2, 2007
Is mixed-handedness a marker of treatment response in posttraumatic stress disorder?: a pilot study
David Forbes, Jessica Carty, Peter Elliott, et al.
European Journal of Preventive Cardiology
|
June 5, 2013
Red flags for persistent or worsening anxiety and depression after an acute cardiac event: a 6-month longitudinal study in regional and rural Australia
Barbara Murphy, Deborah Ludeman, Peter Elliott, et al.
Journal of Cardiopulmonary Rehabilitation and Prevention
|
March 13, 2013
Predicting mortality 12 years after an acute cardiac event: comparison between inhospital and 2-month assessment of depressive symptoms in women
Barbara Murphy, Michelle Rogerson, Marian Worcester, et al.
British Journal of Clinical Pharmacology
|
May 24, 2012
Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man
Ethan Hoffmann, Jeff Wald, Siva Lavu, et al.
Nano Letters
|
August 19, 2021
Spin/Valley Coupled Dynamics of Electrons and Holes at the MoS<sub>2</sub>-MoSe<sub>2</sub> Interface
Abhijeet Kumar, Denis Yagodkin, Nele Stetzuhn, et al.
Journal of Affective Disorders
|
February 5, 2013
A trajectory-based approach to understand the factors associated with persistent depressive symptoms in primary care
Jane Gunn, Peter Elliott, Konstancja Densley, et al.
British Journal of Haematology
|
December 5, 2012
A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma
Rakesh Popat, Torben Plesner, Faith Davies, et al.
British Journal of Clinical Pharmacology
|
January 23, 2014
A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes
Arun Baksi, Oleg Kraydashenko, Alsu Zalevkaya, et al.
Cancer Research
|
December 7, 2007
The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action
Margaret S Lee, Lisa Johansen, Yanzhen Zhang, et al.
Page
of 7